Shares of Walgreens Boots Alliance(NASDAQ: WBA) plunged 25.4% in June, according to data from S&P Global Market Intelligence . News went from bad to worse for Walgreens, which had already been down severely on the year even before the month started. And after another plunge during the last three days of June, the stock was off 54% in the first half of 2024, making it the worst performer in the S&P 500. While pessimism already abounded, Walgreens' fiscal third-quarter results on June 27 only added to its shareholders' woes, with the stock taking yet another leg down. Taking down guidance again In the third quarter, Walgreens posted revenue growth of 2.6%, which was actually ahead of expectations. The problem was on the bottom line, where adjusted (non-GAAP) earnings per share of $0.63 was down a whopping 36.6%, missing even pessimistic analyst expectations of $0.71. Furthermore, the company lowered its full-year adjusted earnings guidance for the second time in 2024 to a range of $2.80 to $2.95, down from the $3.20-to-$3.35 range it had guided in March -- and that was already lowered from the original guidance of $3.40 to $3.50. How did revenue increase while profit decreased? Much of the pressure was felt in Walgreens' pharmacy business, where the concentrated pharmacy benefit manager (PBM) industry is squeezing pharmacies on reimbursement rates. The phenomenon is an industrywide problem. However, unlike some other retail pharmacies, Walgreens doesn't own one of the major PBMs, so it's seeing margin plummet in that important business. Meanwhile, Walgreens also saw its retail sales decline 2.3%, as a cash-strapped consumer appeared to pull back on more discretionary pharmacy purchases. Moreover, the company's acquisition of pharmacy care clinic VillageMD continues to struggle, with the healthcare clinic segment garnering a $220 million operating loss last quarter. While that was a $300 million improvement over the prior year, it still leaves the debt-laden company with an unprofitable unit to deal with. Walgreens has a new CEO, but a turnaround is uncertain On the bright side, Walgreens still forecasts a profitable year, and it has a new CEO in Tim Wentworth, who took over last October, so he hasn't had much time to implement a turnaround. Moreover, Wentworth used to head Express Scripts, one of the three big PBMs, and which is currently owned by Cigna. With PBM experience, he may be able to help reverse the trends that have favored PBMs relative to retail pharmacies. Still, Wentworth has his work cut out for him. Walgreens is nearly $9 billion in debt, not counting operating leases, and its margin is squeezed, so investors would be wise to wait for signs of tangible progress on operational improvement and profitability before trying to time this turnaround. Should you invest $1,000 in Walgreens Boots Alliance right now? Before you buy stock in Walgreens Boots Alliance, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Walgreens Boots Alliance wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $771,034!* Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. TheStock Advisorservice has more than quadrupled the return of S&P 500 since 2002*. See the 10 stocks » *Stock Advisor returns as of July 2, 2024 Billy Duberstein and/or his clients have no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Walgreens Boots Alliance Plunged in June was originally published by The Motley Fool
Why Walgreens Boots Alliance Plunged in June
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...